Facharzt FMH Medizinische Onkologie
Facharzt FMH Medizinische Onkologie (Switzerland)
Systemic Therapies Immuno OncologyEnglish
Exam overviewPractice session
What is the key biological and pharmacological difference between anti-PD-1 monoclonal antibodies (e.g., Pembrolizumab, Nivolumab) and anti-PD-L1 monoclonal antibodies (e.g., Atezolizumab, Durvalumab)?
Loading your practice session…